IBRX Q4 2023 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$139,000+90.4% YoY

Gross Profit

$139,000100.0% margin

Operating Income

-$85M-61430.9% margin

Net Income

-$233M-167907.9% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

+69.5%

Cash Flow

Operating Cash Flow

-$115M

Free Cash Flow

-$123M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$504M

Total Liabilities

$1.1B

Stockholders' Equity

-$587M

Cash & Equivalents

$265M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$139,000	$73,000	+90.4%
Gross Profit	$139,000	-$7M	+102.0%
Operating Income	-$85M	-$84M	-1.4%
Net Income	-$233M	-$108M	-115.7%